Related Experiment Video
Updated: Apr 14, 2026

Gene Transfer for Ischemic Heart Failure in a Preclinical Model
Published on: May 15, 2011
The Current and Future Landscape of SERCA Gene Therapy for Heart Failure: A Clinical Perspective
Carl Hayward1, Nicholas R Banner2, Andrew Morley-Smith1
11Cardiovascular Biomedical Research Unit, Royal Brompton Hospital, SW3 6NP London, United Kingdom.
Abstract:
Gene therapy has been applied to cardiovascular disease for over 20 years but it is the application to heart failure that has generated recent interest in clinical trials. There is laboratory and early clinical evidence that delivery of sarcoplasmic reticulum calcium ATPase 2a (SERCA2a) gene therapy is beneficial for heart failure and this therapy could become the first positive inotrope with anti-arrhythmic properties. In this review we will discuss the rationale for SERCA2a gene therapy as a viable strategy in heart failure, review the published data, and discuss the ongoing clinical trials, before concluding with comments on the future challenges and potential for this therapy.
Related Concept Videos
Gene Therapy
Gene Therapy
Heart Failure II: Pathophysiology
Heart Failure I: Introduction
Pathophysiology of Heart Failure
Heart Failure V: Medical Management

